SOLV · Healthcare

Solventum Corp

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Acquisition / Partnership / DivestitureImportance 64 · Surprise 42
  Solventum announced on August 5, 2026, that it intends to separate its Health Information Systems (HIS) business as part of its portfolio-optimization strategy. HIS generates approximately $1.4 billion in annual sales…
• Guidance and OutlookImportance 51 · Surprise 60
  Solventum raised its full-year 2026 outlook after reporting second-quarter organic sales growth of 9.5%. Management increased guidance for full-year organic sales growth, adjusted diluted EPS and free cash flow.…
• Net Income and ProfitabilityImportance 45 · Surprise 64
  Adjusted diluted EPS was $2.55 in the second quarter, 50.9% above the year-ago result and $1.04 above the analyst estimate. GAAP net income declined despite the adjusted earnings increase. Adjusted profitability and…
• Revenue Performance and MixImportance 37 · Surprise 32
  Solventum reported second-quarter 2026 sales of $2.21 billion, up 2.2% year over year. Organic sales increased 9.5% for the quarter ended June 30, 2026. All business segments reportedly delivered organic growth,…
• Market Demand TrendsImportance 25 · Surprise 32
  Solventum reported resilient demand across its healthcare businesses ahead of second-quarter earnings. Organic sales increased 9.5% in Q2 2026, with third-party coverage describing growth across all segments. The…
• Supply Chain ConstraintsImportance 25 · Surprise 42
  Solventum experienced near-term operational disruption from an enterprise-resource-planning system cutover. Third-party coverage said the ERP transition affected the timing of reported results, including benefits from…
• Competition and Pricing PressureImportance 17 · Surprise 24
  Third-party reporting identified pricing challenges as an offset to Solventum’s resilient healthcare demand. Coverage also cited tariffs and funding pressure as factors affecting providers and suppliers in the…

News · 2026-08-07

• Acquisition / Partnership / DivestitureImportance 64 · Surprise 42
  Solventum announced on August 5, 2026, that it intends to separate its Health Information Systems (HIS) business as part of its portfolio-optimization strategy. HIS generates approximately $1.4 billion in annual sales…
• Guidance and OutlookImportance 51 · Surprise 60
  Solventum raised its full-year 2026 outlook after reporting second-quarter organic sales growth of 9.5%. Management increased guidance for full-year organic sales growth, adjusted diluted EPS and free cash flow.…
• Net Income and ProfitabilityImportance 45 · Surprise 64
  Adjusted diluted EPS was $2.55 in the second quarter, 50.9% above the year-ago result and $1.04 above the analyst estimate. GAAP net income declined despite the adjusted earnings increase. Adjusted profitability and…
• Market Demand TrendsImportance 25 · Surprise 32
  Solventum reported resilient demand across its healthcare businesses ahead of second-quarter earnings. Organic sales increased 9.5% in Q2 2026, with third-party coverage describing growth across all segments. The…

News · 2026-08-06

• Net Income and ProfitabilityImportance 45 · Surprise 64
  Adjusted diluted EPS was $2.55 in the second quarter, 50.9% above the year-ago result and $1.04 above the analyst estimate. GAAP net income declined despite the adjusted earnings increase. Adjusted profitability and…

10-Q · 2026-08-05

• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Cash and cash equivalents decreased by $475 million in the first six months of 2026, compared with a $268 million decrease in the first six months of 2025. Operating cash flow declined year over year primarily because…
• Property Investment IncreaseImportance 68 · Surprise 58
  Net property, plant and equipment increased 18.0% to $1,565 million at June 30, 2026 from $1,326 million at December 31, 2025. Gross property, plant and equipment rose to $3,455 million from $3,193 million over the…
• Market Demand TrendsImportance 58 · Surprise 42
  Second-quarter 2026 sales benefited from approximately $125 million of advanced customer orders placed ahead of Solventum’s July 2026 U.S. ERP deployment. Management expects third-quarter sales to be negatively…
• Interest Rate and Refinancing ExposureImportance 56 · Surprise 24
  Solventum had $5.0 billion of senior notes outstanding at June 30, 2026, with maturities ranging from 2027 through 2064 and fixed interest rates from 5.31% to 6.09%. The Company also had a $1.0 billion three-year…
• Revenue Performance and MixImportance 54 · Surprise 40
  Second-quarter 2026 net sales increased 2.2% year over year to $2.209 billion, with 9.5% organic growth offset by an 8.3% negative impact from divestitures and other items. Six-month net sales decreased 0.4% to $4.216…
• Liquidity and Debt PositionImportance 54 · Surprise 14
  Total debt was $5,079 million at June 30, 2026, compared with $5,035 million at December 31, 2025. Long-term debt excluding current maturities was $4,573 million at June 30, 2026, down from $5,035 million at year-end…
• Geographic Revenue CommentaryImportance 54 · Surprise 40
  United States sales were $1.313 billion in the second quarter of 2026, representing 59.4% of worldwide sales, and increased 10.4% on a reported basis. International sales represented 40.6% of worldwide sales and…
• Operating Expense TrendsImportance 54 · Surprise 40
  SG&A increased to 42.0% of sales in the second quarter of 2026 from 35.7% in the prior-year quarter, and to 41.6% from 36.4% for the first six months. The increase was driven by accrued legal expenses and higher costs…
• Income Tax Rate ChangesImportance 53 · Surprise 82
  The effective tax rate for the second quarter increased to 14.4% from 12.5% in the prior-year quarter, primarily because of an unfavorable geographic mix of earnings. The six-month effective tax rate was 15.0%,…
• Gross Margin DriversImportance 51 · Surprise 50
  Cost of product declined to 47.5% of sales in the second quarter of 2026 from 51.9% in the prior-year quarter, a 4.4 percentage-point improvement. For the first six months, cost of product decreased to 49.9% of sales…
• FX / Currency HeadwindsImportance 50 · Surprise 24
  Solventum operates through foreign subsidiaries and uses foreign-currency forward contracts and cross-currency swaps to manage exchange-rate exposure. At June 30, 2026, the Company had approximately $1.2 billion of…
• Acquisition / Partnership / DivestitureImportance 47 · Surprise 60
  On August 5, 2026, Solventum announced its intention to pursue a separation of the Health Information Systems business as part of portfolio optimization. The company will evaluate multiple separation pathways intended…
• Trade Policy and TariffsImportance 47 · Surprise 60
  The U.S. Supreme Court ruled on February 20, 2026 that the International Emergency Economic Powers Act did not authorize presidential tariffs, and tariffs imposed under that statute are expected to be fully refunded.…
• Liquidity and Cash PositionImportance 44 · Surprise 46
  Cash and cash equivalents declined to $403 million at June 30, 2026 from $878 million at December 31, 2025. Foreign subsidiaries held approximately $291 million of June 30 cash, while the United States held…
• Product Liability LawsuitImportance 40 · Surprise 42
  3M is a defendant in approximately 8,400 U.S. lawsuits and one Canadian putative class action alleging that the Bair Hugger patient warming system caused surgical-site infections. Solventum agreed under its Separation…
• Headcount / RestructuringImportance 37 · Surprise 42
  In November 2025, Solventum approved the four-year “Transform for the Future” global initiative to support its long-term growth strategy and compete in a changing healthcare environment. The program includes…
• Capital Return ProgramImportance 34 · Surprise 42
  Solventum repurchased 3.9 million common shares during the second quarter of 2026 and 4.8 million shares during the six months ended June 30, 2026. The repurchases were conducted through open-market transactions under…
• Product Portfolio RationalizationImportance 34 · Surprise 42
  MedSurg growth was partially offset by Solventum’s SKU rationalization program. The rationalization had a larger impact on the Infection Prevention and Surgical Solutions business. The filing does not quantify the…
• Supply Chain ConstraintsImportance 29 · Surprise 24
  Solventum purchases the majority of its materials and services as needed, without unconditional commitments, which provides procurement flexibility. In limited cases, the company uses take-or-pay and similar vendor…
• Products and TechnologyImportance 26 · Surprise 24
  MedSurg growth was driven by I.V. site management products, including Tegaderm CHG, and by negative pressure wound therapy in Advanced Wound Care. Dental Solutions growth came from restorative and prevention solutions…
• Supply Chain and SourcingImportance 17 · Surprise 24
  Solventum operates a global supply chain and sourcing organization that includes products sourced under master supply and transition manufacturing agreements with 3M. Management stated that changes in the global…

8-K · 2026-08-05

• Liquidity and Debt PositionImportance 81 · Surprise 64
  Cash and cash equivalents declined to $403 million at June 30, 2026, from $878 million at December 31, 2025. Long-term debt was $4.573 billion, while short-term borrowings and the current portion of long-term debt…
• Segment Revenue PerformanceImportance 78 · Surprise 64
  Second-quarter MedSurg revenue increased $154 million to $1.372 billion, with operating income rising to $355 million from $210 million and operating margin expanding to 25.8% from 17.3%. Dental Solutions revenue grew…
• Capital Return ProgramImportance 77 · Surprise 82
  Solventum purchased $355 million of treasury stock during the first six months of 2026, compared with no treasury-stock purchases in the prior-year period. Treasury stock was $355 million at June 30, 2026, representing…
• Litigation and Legal RiskImportance 77 · Surprise 82
  Solventum reported $157 million of certain litigation-related costs in second-quarter 2026 adjusted operating-income reconciliations, compared with $8 million in the second quarter of 2025. For the first six months of…
• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  Solventum announced its intent to separate the Health Information Systems business segment. Health Information Systems generated second-quarter sales of $354 million and operating income of $145 million, representing a…
• Headcount / RestructuringImportance 65 · Surprise 82
  Second-quarter restructuring costs totaled $42 million, including $11 million of employee termination costs and $31 million of consulting, asset write-down and dedicated-employee costs. Six-month restructuring costs…
• Guidance / OutlookImportance 62 · Surprise 68
  Solventum raised its full-year 2026 organic sales growth guidance to 2.5%–3.0%, compared with the prior range of 2.0%–3.0%. Excluding approximately 100 basis points of SKU-exit impact, the company expects organic sales…
• Operating Expense TrendsImportance 55 · Surprise 66
  Second-quarter SG&A increased 20.1% year over year to $927 million from $772 million. The increase primarily reflected higher separation-related costs and net legal costs, while adjusted SG&A as a percentage of sales…
• Revenue Performance and MixImportance 54 · Surprise 40
  Second-quarter 2026 sales were $2.209 billion, up 2.2% year over year on a reported basis and 9.5% organically. MedSurg sales increased 12.7% to $1.372 billion, including Advanced Wound Care sales of $537 million, up…
• Operating Margin DriversImportance 54 · Surprise 74
  GAAP operating income declined to $181 million from $214 million, reducing operating margin to 8.2% from 9.9%. The 170-basis-point margin decline was primarily caused by net legal costs, separation costs and…
• Operating Cash Flow TrendsImportance 51 · Surprise 64
  Second-quarter operating cash flow increased 34.3% to $227 million from $169 million. Free cash flow increased 144.1% to $144 million from $59 million after $83 million of capital expenditures. The quarterly cash-flow…
• Market Demand TrendsImportance 48 · Surprise 40
  Solventum reported second-quarter organic sales growth of 9.5%, reflecting volume and product mix across all reportable segments. The company said advance orders placed ahead of enterprise-resource-planning cutovers…
• Gross Margin DriversImportance 45 · Surprise 50
  GAAP gross profit increased to $1.286 billion from $1.175 billion in the second quarter. GAAP gross margin rose to 58.2% from 54.4%, while adjusted gross margin increased to 60.1% from 56.0%. The company attributed the…
• Income Tax Rate ChangesImportance 45 · Surprise 64
  The second-quarter effective tax rate increased to 14.4% from 12.5%, while income-tax expense rose to $15 million from $13 million. For the first six months, the effective tax rate was 15.0%, compared with a negative…
• Capital ExpendituresImportance 40 · Surprise 30
  Solventum spent $167 million on property, plant and equipment in the first six months of 2026, down from $219 million in the prior-year period. Second-quarter capital expenditures were $83 million, compared with $110…
• Supply Chain Tariff ImpactImportance 25 · Surprise 42
  Solventum reported that GAAP and adjusted gross margins increased in the second quarter of 2026, driven by a refund under the U.S. Inflation Reduction Act excise tax, or IEEPA, tariff regime. The company also cited the…

8-K · 2026-08-05

• Acquisition / Partnership / DivestitureImportance 64 · Surprise 42
  Solventum intends to pursue a separation of its Health Information Systems business, which generated $1.4 billion in net sales for the twelve months ended December 31, 2025. The company is evaluating alternatives…
• Market Demand TrendsImportance 49 · Surprise 32
  Health Information Systems generated $1.4 billion in annual sales for the twelve months ended December 31, 2025. It operates in an approximately $10 billion addressable market estimated to grow 5–6% annually. The…
• Products and TechnologyImportance 17 · Surprise 24
  Health Information Systems is built on more than 40 years of medical coding expertise and processes approximately 660 million clinical documents monthly. Its product portfolio includes revenue cycle management,…
• Geographic Market CommentaryImportance 16 · Surprise 6
  Health Information Systems solutions are deployed across more than 30 countries, with more than 75% of U.S. hospitals using the business’s solutions. The company identified international markets undergoing payment…
• Customer DynamicsImportance 10 · Surprise 6
  Health Information Systems solutions are used by more than 75% of U.S. hospitals. Its software is deployed through long-term contracts and deeply embedded workflows with health systems, physician practices and…

News · 2026-08-05

• Acquisition / Partnership / DivestitureImportance 64 · Surprise 42
  Solventum announced on August 5, 2026, that it intends to separate its Health Information Systems (HIS) business as part of its portfolio-optimization strategy. HIS generates approximately $1.4 billion in annual sales…
• Guidance and OutlookImportance 51 · Surprise 60
  Solventum raised its full-year 2026 outlook after reporting second-quarter organic sales growth of 9.5%. Management increased guidance for full-year organic sales growth, adjusted diluted EPS and free cash flow.…
• Net Income and ProfitabilityImportance 45 · Surprise 64
  Adjusted diluted EPS was $2.55 in the second quarter, 50.9% above the year-ago result and $1.04 above the analyst estimate. GAAP net income declined despite the adjusted earnings increase. Adjusted profitability and…
• Revenue Performance and MixImportance 37 · Surprise 32
  Solventum reported second-quarter 2026 sales of $2.21 billion, up 2.2% year over year. Organic sales increased 9.5% for the quarter ended June 30, 2026. All business segments reportedly delivered organic growth,…

News · 2026-08-04

• Market Demand TrendsImportance 25 · Surprise 32
  Solventum reported resilient demand across its healthcare businesses ahead of second-quarter earnings. Organic sales increased 9.5% in Q2 2026, with third-party coverage describing growth across all segments. The…